Cargando…
Development of a highly sensitive method for detection of FLT3D835Y
BACKGROUND: Acute myeloid leukemia (AML) is a malignant hematological neoplasm of myeloid progenitor cells. Mutations of FLT3 in its tyrosine kinase domain (FLT3-TKD) are found in ~ 8% of patients with AML, with D835Y as the most common substitution. This mutation activates survival signals that dri...
Autores principales: | Guo, Yao, Sun, Honghua, Zhang, Dengyang, Zhao, Yuming, Shi, Mingxia, Yang, Ming, Xing, Shu, Fu, Xueqi, Bin, Ting, Lu, Bo, Wu, Shunjie, Xu, Xiaojun, Xu, Xuesong, Chen, Yun, Zhao, Zhizhuang Joe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424998/ https://www.ncbi.nlm.nih.gov/pubmed/32817792 http://dx.doi.org/10.1186/s40364-020-00210-7 |
Ejemplares similares
-
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
por: Guo, Yao, et al.
Publicado: (2012) -
Identification of an orally available compound with potent and broad FLT3 inhibition activity
por: Chen, Yun, et al.
Publicado: (2015) -
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
por: Zhang, Dengyang, et al.
Publicado: (2021) -
Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021) -
FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)